Allergies impact the lives of millions globally. They interfere with the quality of life and the ability to enjoy simple things, like spending time outdoors, eating certain foods, or even working in specific environments. For many people, this goes beyond a seasonal inconvenience; it is a chronic problem that demands constant management. Conventional treatments like antihistamines and avoidance strategies provide short-term relief, but fail to address the core issue, leaving people tethered to these solutions indefinitely.

At BOME Therapeutics, we’re focusing on an entirely different approach to allergy care. Our mission is to redefine how allergies are treated. By using our proprietary Antigen Delivery by Precipitation (ADBP) technology, we believe we’ve unlocked a safer, more efficient way to train the immune system and deliver lasting relief.

This article will take you through the science behind allergen immunotherapy, explain the limitations of current treatments, and detail how our groundbreaking technology is setting the stage for a new era in allergy immunotherapy.

Decades of research into allergen immunotherapy have primarily relied on two delivery methods: injections (commonly known as allergy shots) and sublingual formulations (tablets or drops placed under the tongue). Although these methods have proven effective for some, they pose critical challenges that limit their broader impact.

Lengthy Treatment Timelines
Traditional immunotherapy can require years of consistent treatment, often involving weekly or biweekly appointments initially, followed by monthly maintenance doses. For patients, these extended timeframes can be impractical, leading to a significant drop-out rate before achieving full tolerance.

Variable Effectiveness
The success of existing therapies depends on numerous factors, including the allergen and the individual’s immune response. For potent allergens like urushiol, success has been particularly elusive. Developing effective vaccines for these specific triggers has remained a challenge for researchers for over a century.

Safety Concerns
Traditional methods introduce allergens in a way that allows them to spread systemically throughout the body, which increases the risk of severe allergic reactions. This necessitates administering treatments in controlled clinical settings with emergency management protocols, making the entire process less accessible and convenient.

Formulation Obstacles
Certain allergens pose difficulties in stabilization and delivery. For example, urushiol is an oily compound that does not dissolve in water, making it unsuitable for the aqueous injection solutions typically used in immunotherapy formulations. This had long been a roadblock in developing reliable treatments for poison ivy and poison oak allergies.

Taken together, these challenges emphasize the need for smarter, faster, and safer approaches. BOME Therapeutics has developed a solution that directly addresses these limitations while expanding the possibilities for immunotherapy beyond allergens.

At BOME Therapeutics, we are completely rethinking how immunotherapy works. Our initial focus is on addressing one of the most prevalent allergens in the United States: urushiol, the compound responsible for allergic reactions to poison ivy and poison oak.

Every year, millions of Americans suffer from urushiol-related contact dermatitis. The implications range from physical discomfort to loss of productivity, particularly for those whose professions bring them into frequent contact with these plants. Forestry workers, firefighters, and outdoor enthusiasts often have no option for avoidance. Treatment costs and economic losses add up, creating a significant societal burden.

Despite previous efforts to develop an immunotherapy treatment, no FDA-approved vaccine currently exists to generate tolerance against poison ivy and poison oak.

Our proprietary platform, Antigen Delivery by Precipitation (ADBP), is the foundation for our efforts to develop more effective and accessible treatments. At its core, ADBP technology addresses the formulation, delivery, and immune-response challenges faced by earlier approaches to immunotherapy.

Here’s how it works:

Precision Formulation
The allergen, urushiol, is processed and dissolved in a clinical grade solvent, where it remains stable.

Targeted Injection
A small volume of this solution is injected directly into tissue, such as a muscle, where it will remain localized.

Controlled Precipitation Process
Once injected, the solution is rapidly dispersed by the water content in the surrounding muscle tissue. This triggers the allergen to precipitate out of the solution, forming microscopic particles recognized by the immune system.

Effective Immune Activation
These particles are expertly calibrated to the perfect dimensions for uptake by antigen-presenting cells (APCs). The APCs transport these particles to lymph nodes, sending clear signals that switch the immune response from sensitivity to tolerance.

This technology reinvents the way allergens interact with the immune system, offering precision that traditional immunotherapy cannot match.

ADBP technology represents a leap forward in allergen immunotherapy, addressing long-standing issues in safety, efficacy, and treatment efficiency. Here’s why it stands out:

Enhanced Effectiveness
By generating a dense “cloud” of allergen particles specifically engineered for efficient immune cell uptake, ADBP creates a robust immunological response. Early human studies with our poison ivy vaccine yielded a 90% success rate, with remaining non-responders achieving tolerance through a single booster dose.

Improved Safety Profile
Because the allergen particles precipitate and remain localized at the injection site, the risk of systemic allergic reactions is drastically reduced. Patients benefit from a safer treatment experience that significantly lowers the likelihood of adverse effects.

Scalable and Versatile Applications
While our initial focus is poison ivy, ADBP is designed to be a flexible platform. Its principles can be applied to other allergens, such as foods and insect venoms, as well as other therapeutic areas, including oncology and infectious diseases. This adaptability could open doors to revolutionary advances across multiple industries.

Shorter, More Convenient Treatment Courses

Unlike traditional approaches, which take years, ADBP enables shorter protocols with fewer sessions. This reduces the time burden on patients while maintaining high efficacy rates, making treatment more practical and appealing.

To meet regulatory and scientific standards, achieving a consistent and predictable vaccine is paramount. One of the challenges with urushiol lies in its natural variability. Different plants produce urushiol molecules in slightly different ratios, which can affect the allergen profile.

At BOME Therapeutics, we’ve solved this problem by cultivating poison ivy plants in a tightly controlled greenhouse environment. Utilizing plants selected for their ideal urushiol profiles, we ensure consistency in our vaccine’s raw materials.

At BOME Therapeutics, we’re shaping the future of allergy care and beyond. By pushing the limits of science, our proprietary ADBP technology opens doors to smarter, safer, and more effective treatment solutions for challenges that have long confounded the medical field.

Urushiol-related allergies are just the beginning. The precision and scalability behind ADBP technology hold promise for transforming care for a wide array of conditions. Imagine a world where children with severe peanut allergies can indulge in birthday celebrations without fear, or where individuals hypersensitive to insect venom can explore the outdoors freely. ADBP technology could turn these possibilities into reality, offering lasting relief to millions still reliant on temporary or cumbersome treatments today.

What if we could harness ADBP to develop personalized treatments that cater to an individual’s unique immune profile? What if public health initiatives in regions heavily impacted by insect-borne diseases could deploy ADBP-based solutions to protect entire populations from venom allergies? These are goals within our reach.

What excites us most is the ability to dream even bigger. From advancing personalized therapies tailored to an individual’s immune profile to developing scalable solutions for global health challenges, ADBP is more than a platform; it’s the key to unlocking groundbreaking possibilities in medicine.

At BOME Therapeutics, we’re leveraging science to create better clinical treatments for tomorrow. Through creative and conventional thinking, we’re demonstrating how immunotherapy can advance beyond current solutions.